Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2026 · second_quarter · Q2
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
CDMRP's PRCRP
Source: Senate LDA
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Welcome Back to the Health Care Workforce Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
HELP Copays Act
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
H.R.830 - HELP Copays Act, Cancer Drug Parity Act (not introduced yet)
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2023
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Cancer Drug Parity Act of 2019
Client: INTERNATIONAL MYELOMA FOUNDATION · Firm: INTERNATIONAL MYELOMA FOUNDATION
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Access Issues, Cancer Drug Parity Act, Safe Step Act, Seniors Timely Access to Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2026 · first_quarter · 1A
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
Access Issues, Cancer Drug Parity Act, Safe Step Act, Seniors Timely Access to Care Act
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2026 · first_quarter · Q1
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,
CDMRP's PRCRP
Access Issues, Cancer Drug Parity Act, Safe Step Act, Seniors Timely Access to Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · fourth_quarter · 4A
Access Issues, Cancer Drug Parity Act, Safe Step Act
CDMRP's PRCRP
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · fourth_quarter · Q4
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Access Issues, Cancer Drug Parity Act, Safe Step Act
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · third_quarter · Q3
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Access Issues, Cancer Drug Parity Act, Safe Step Act
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · second_quarter · 2A
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Access Issues, Cancer Drug Parity Act, Step Therapy Reform
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · second_quarter · Q2
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Access Issues, Cancer Drug Parity Act, Step Therapy Reform
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2025 · first_quarter · Q1
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
Access Issues, Cancer Drug Parity Act, Step Therapy Reform
CDMRP's PRCRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · fourth_quarter · Q4
Cancer research funding-Labor HHS bill
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · third_quarter · 3A
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · third_quarter · Q3
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
Cancer research funding-Labor HHS bill
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · second_quarter · 2A
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · second_quarter · Q2
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · first_quarter · 1A
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2024 · first_quarter · Q1
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2023 · fourth_quarter · 4A
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2023 · fourth_quarter · Q4
Cancer research funding-Labor HHS bill
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2023 · third_quarter · Q3
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2023 · second_quarter · Q2
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
S. 2039, Cancer Drug Parity Act, HELP Copays Act
Cancer research funding-Labor HHS bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2023 · first_quarter · Q1
Cancer research funding-Labor HHS bill
Defense Appropriations: CDMRP (advocate for blood cancer research funding)
H.R.830 - HELP Copays Act, Cancer Drug Parity Act (not introduced yet)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · fourth_quarter · Q4
CDMRP
Oral Parity-Cancer Drug Parity Act; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · third_quarter · 3A
CDMRP
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · third_quarter · 3A
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · third_quarter · 3A
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · third_quarter · Q3
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · second_quarter · Q2
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2022 · first_quarter · Q1
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2021 · fourth_quarter · Q4
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2021 · third_quarter · Q3
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2021 · second_quarter · Q2
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2021 · first_quarter · 1A
CDMRP
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2021 · first_quarter · Q1
CDMRP
Oral Parity; CDMRP; Cancer Research Funding
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · fourth_quarter · 4A
CDMRP
Department of Defense Cancer Research Program
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · fourth_quarter · Q4
Department of Defense Cancer Research Program
HR 1730/S.741 Cancer Issues - Multiple Myeloma
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · third_quarter · 3A
Department of Defense Cancer Research Program
HR 1730/S.741 Cancer Issues - Multiple Myeloma
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · third_quarter · Q3
CDMRP
Department of Defense Cancer Research Program
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · second_quarter · Q2
HR 1730/S.741 Cancer Issues - Multiple Myeloma
CDMRP
Department of Defense Cancer Research Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · first_quarter · 1A
CDMRP
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Department of Defense Cancer Research Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2020 · first_quarter · Q1
CDMRP
HR 1730/S.741 Cancer Issues - Multiple Myeloma
Department of Defense Cancer Research Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · fourth_quarter · Q4
Department of Defense Oral Parity
CDMRP
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · second_quarter · 2A
Department of Defense Oral Parity
CDMRP
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · third_quarter · 3A
CDMRP
CDMRP
Department of Defense Oral Parity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · third_quarter · Q3
CDMRP
Department of Defense Oral Parity
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · second_quarter · Q2
CDMRP
Department of Defense Oral Parity
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · first_quarter · 1A
CDMRP
CDMRP
Department of Defense Oral Parity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2019 · first_quarter · Q1
CDMRP
Department of Defense Oral Parity
CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · fourth_quarter · 4A
DoD - CDMRP
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
DoD Approrprations - CDMRP NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · fourth_quarter · Q4
DoD - CDMRP
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
DoD Approrprations - CDMRP NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · third_quarter · Q3
DoD - CDMRP
DoD Approrprations - CDMRP NIH Funding
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · second_quarter · 2A
DoD - CDMRP
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
DoD Approrprations - CDMRP NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · second_quarter · Q2
DoD Approrprations - CDMRP NIH Funding
DoD - CDMRP
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · first_quarter · 1A
DoD - CDMRP
DoD Approrprations - CDMRP NIH Funding
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2018 · first_quarter · Q1
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
DoD Approrprations - CDMRP NIH Funding
DoD - CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2017 · fourth_quarter · Q4
DoD Approrprations - CDMRP NIH Funding
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding Affordable Care Act
DoD - CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2017 · third_quarter · Q3
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding
DoD Approrprations - CDMRP NIH Funding
DoD - CDMRP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2017 · second_quarter · Q2
DoD Approrprations - CDMRP NIH Funding
DoD - CDMRP
Cancer Drug Coverage Act DoD Appropriations - CDMRP NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MYELOMA FOUNDATION via INTERNATIONAL MYELOMA FOUNDATION
2017 · second_quarter · RA
Cancer Drug Coverage DoD Appropriations - CDMRP NIH Funding
Cancer Drug Coverage DoD Appropriations - CDMRP NIH Funding
Cancer Drug Coverage DoD Appropriations - CDMRP NIH Funding
Cancer Drug Coverage DoD Appropriations - CDMRP NIH Funding